Analysts Set Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Target Price at $6.25

Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) have received an average recommendation of "Buy" from the six research firms that are presently covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $6.25.

Several brokerages have weighed in on TNYA. Morgan Stanley dropped their price objective on Tenaya Therapeutics from $15.00 to $5.00 and set an "overweight" rating for the company in a report on Wednesday, March 12th. Canaccord Genuity Group cut their price objective on shares of Tenaya Therapeutics from $18.00 to $6.00 and set a "buy" rating for the company in a research report on Thursday, March 13th. HC Wainwright reiterated a "buy" rating and set a $5.00 price objective on shares of Tenaya Therapeutics in a research note on Friday, April 25th. Finally, Chardan Capital restated a "buy" rating and issued a $9.00 target price on shares of Tenaya Therapeutics in a research report on Friday, May 9th.

Tenaya Therapeutics Stock Performance

Shares of TNYA stock traded down $0.01 on Thursday, hitting $0.59. The company's stock had a trading volume of 1,500,681 shares, compared to its average volume of 2,593,973. Tenaya Therapeutics has a fifty-two week low of $0.36 and a fifty-two week high of $4.06. The company has a market capitalization of $96.46 million, a PE ratio of -0.41 and a beta of 2.91. The stock's 50 day moving average is $0.48 and its 200-day moving average is $1.09.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.06). On average, research analysts forecast that Tenaya Therapeutics will post -1.35 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Woodline Partners LP grew its holdings in shares of Tenaya Therapeutics by 30,563.2% during the 1st quarter. Woodline Partners LP now owns 5,916,167 shares of the company's stock valued at $3,373,000 after purchasing an additional 5,896,873 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Tenaya Therapeutics by 20,670.3% during the fourth quarter. JPMorgan Chase & Co. now owns 5,155,596 shares of the company's stock worth $7,373,000 after buying an additional 5,130,774 shares during the last quarter. AQR Capital Management LLC acquired a new position in shares of Tenaya Therapeutics during the first quarter worth $442,000. Northern Trust Corp lifted its stake in shares of Tenaya Therapeutics by 6.2% in the 4th quarter. Northern Trust Corp now owns 472,479 shares of the company's stock valued at $676,000 after acquiring an additional 27,632 shares during the last quarter. Finally, Nuveen Asset Management LLC boosted its holdings in shares of Tenaya Therapeutics by 25.2% during the 4th quarter. Nuveen Asset Management LLC now owns 345,192 shares of the company's stock valued at $494,000 after acquiring an additional 69,377 shares in the last quarter. Institutional investors and hedge funds own 90.54% of the company's stock.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.